The US Food and Drug Administration continued to crack down on lack of sterility assurance, cross-contamination and poor investigations in recent inspection reports and warning letters to pharma companies.
An aging facility still churning out a former blockbuster drug as generic competition encroaches was cited for microbiological
Meanwhile, the agency criticized another firm for combining drug compounding and